Document:

EX-4.5

 Exhibit 4.5 

Employment Agreement 
 This Agreement is made on
6 December 2016, between 
  

	(1)	 ASTRAZENECA UK LIMITED (registered in England and Wales under number 3674842) whose registered office is at 1
Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (“AstraZeneca”); and 

  

	(2)	 MARC DUNOYER whose address for service is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA
(“You”). 

  

	1.	 APPOINTMENT 

 

	 	 AstraZeneca will employ you as Chief Financial Officer on the terms of this employment agreement
(“Agreement”). 

  

	2.	 SCOPE OF YOUR EMPLOYMENT 

 

	2.1	 During your Employment you will: 

 

	 	(a)	 work on a full-time basis for AstraZeneca and devote all of your working time, attention and skill to the business of
the Group; 

  

	 	(b)	 diligently perform those duties, obey directions and exercise powers consistent with your position as may be assigned to
you by the Chief Executive Officer of AstraZeneca (“CEO”) or the Board; 

  

	 	(c)	 comply with all applicable laws and guidance (including rules issued from time to time by national regulatory bodies in
relation to insider trading), AstraZeneca’s rules, regulations, policies and procedures from time to time in force; and 

  

	 	(d)	 not be directly or indirectly engaged in any business or activity that the Board reasonably considers may be or become
harmful to the interests of the Group or which might reasonably be considered to interfere with the performance of your Employment without the prior written consent of the Board. 

 

	3.	 PLACE OF WORK 

 

	 	 Your place of work will be AstraZeneca’s offices at Pancras Square in London, but AstraZeneca may require you to
travel and to work at any place on either a temporary or an indefinite basis. 

  

	4.	 REMUNERATION 

 

	4.1	 Your base salary will be paid at the rate of £707,472 per annum by equal monthly instalments in arrears by bank
transfer. Tax and any sums you owe to AstraZeneca may be deducted from your salary, as appropriate. No sums you owe to AstraZeneca will be deducted from your salary without reasonable prior notice to you. Your salary will be reviewed, but not
necessarily increased, in February each year with any changes backdated to 1 January of that year. No salary review will occur after either party has given notice to terminate your Employment. 

 

	4.2	 During your Employment you will be entitled to participate in such discretionary performance-related bonus schemes and
share incentive schemes as the Board may determine. Details of any awards and participation conditions will be notified to you separately. 

  

	4.3	 In the year in which your Employment terminates, any performance-related bonus will be determined at the discretion of
the Board, taking into account Group and your performance and the period you have worked during that bonus year. 

	4.4	 AstraZeneca operates a flexible benefits arrangement called AZ Advantage, which gives you flexibility over your
benefits. Your annual Advantage Fund (which includes your base salary) is £935,325. Your Advantage Fund includes AstraZeneca’s funding for your pension. Contributions you elect to make to your pension will be deducted from your Advantage
Fund. The balance of your Advantage Fund can be used to purchase a range of benefits or taken in cash. 

  

	5.	 EXPENSES 

 

	 	 AstraZeneca will reimburse you for all expenses you reasonably incur in the proper performance of your duties in
accordance with AstraZeneca’s expenses policy. 

  

	6.	 HOLIDAYS 

 

	6.1	 You will be entitled, in addition to all public holidays normally observed in England, to 22 working days’ paid
holiday in each holiday year (being the period from 1 July to 30 June). You may take holiday at such times as are agreed with the CEO. 

  

	6.2	 During the holiday years in which your Employment commences or terminates, your entitlement to holiday shall accrue on a
pro rata basis for each completed calendar month of service during the relevant year. 

  

	6.3	 If, on the termination of your Employment, you have exceeded your accrued holiday entitlement the excess, calculated on
the basis that each day of paid holiday is equivalent to 1/260 of your base salary, may be deducted by AstraZeneca from any sums due to you. If you have any unused holiday entitlement, AstraZeneca may pay you in lieu or require you to use it during
your notice period. 

  

	6.4	 Holiday entitlement for one holiday year cannot be taken in subsequent holiday years unless agreed by the CEO. If you do
not take holiday in the appropriate holiday year you will lose it. 

  

	7.	 SICKNESS BENEFITS 

 

	7.1	 AstraZeneca will pay your salary and provide contractual benefits for up to 130 working days’ absence due to
medically certified illness in any period of 12 calendar months or for the first 130 working days’ of absence in any one continuous period. 

  

	7.2	 AstraZeneca can require you to undertake medical examinations with a doctor of AstraZeneca’s choice. AstraZeneca
can receive a copy of any report produced in connection with all such examinations and to discuss the contents of the report with the doctor who produced it. 

 

	8.	 PENSION 

 

	 	 During your Employment you will be entitled to participate in the AstraZeneca Group Self Invested Personal Pension Plan
(“GSIPP”) as it exists on the effective date of this Agreement and any successor plans, subject to the applicable rules. 

  

	9.	 DURATION OF YOUR EMPLOYMENT 

 

	9.1	 Your Employment began on 15 June 2013 and will continue until terminated by either you or AstraZeneca by giving 12
months’ notice in writing to the other. 

  

	9.2	 At any time during any period of notice given under clause 9.1 (whether given by AstraZeneca or by you), you may be
placed on “garden leave” in which case the Group will not be under any obligation to provide work to you. During garden leave AstraZeneca will have the right to assign you reduced or alternative duties, limit or terminate your access to
Group IT systems, exclude you from any premises of the Group, remove you from any or all directorships and offices, require you to refrain from business contact with any customers, agents, contractors or employees of the Group and to take any
holiday which has accrued under clause 6. 

  
 2 

	9.3	 During garden leave you will remain a senior employee, subject to all continuing express and implied obligations to
AstraZeneca, and you will continue to be paid salary and to receive other contractual benefits, subject to the usual rules of any relevant scheme or policy. 

  

	10.	 TERMINATION 

 

	10.1	 Either party may terminate your Employment in accordance with clause 9.1, including in circumstances where you are
absent due to ill health and would otherwise receive permanent health insurance benefits. You will be required to mitigate your loss if AstraZeneca terminates your Employment without requiring you to work for some or all of your notice period.

  

	10.2	 AstraZeneca may terminate your Employment at any time with immediate effect and pay a sum in lieu of notice in full and
final settlement of any claims you may have against the Group equal to: 

  

	 	(a)	 the base salary which you would have received during the notice period if notice had been given (or, if notice has
already been given, during the remainder of the notice period) (the “Relevant Period”); and 

  

	 	(b)	 the cost to AstraZeneca of funding any contractual benefit arrangement operated by AstraZeneca from time to time in
respect of your Employment during the Relevant Period. 

  

	10.3	 Notwithstanding any other provisions of this Agreement, AstraZeneca may terminate your Employment summarily for Cause
(by serving written notice on you to that effect) and with no liability to make any further payment to you (other than in respect of amounts accrued and due on termination of your Employment). 

 

	10.4	 If AstraZeneca believes that it may be entitled to terminate your Employment for Cause, it will be entitled to suspend
you on full pay for so long as it considers appropriate. If you are suspended in this way, AstraZeneca will still have the right to terminate your Employment on the same or another ground at a later date. 

 

	10.5	 You will return all Confidential Information and AstraZeneca equipment at the request of AstraZeneca when your
employment terminates or if you are placed on garden leave. If requested by the Board, you will also resign from all offices, trusteeships and committee memberships held by you in the Group by virtue of your Employment and will transfer any
qualifying shares held by you as nominee for the Group. 

  

	11.	 DIRECTORS AND OFFICERS LIABILITY INSURANCE

  

	 	 The Group will maintain Directors’ and Officers’ liability insurance during your Employment to the fullest
extent permitted by law in accordance with AstraZeneca’s policy. 

  

	12.	 CONFIDENTIAL INFORMATION AND INTELLECTUAL
PROPERTY 

  

	 	 You will keep secret and will not, whether during or after your Employment: divulge or communicate to any person,
company, business entity or other organisation; use for your own purposes or for any purposes other than those of the Group; or through any failure to exercise due care and diligence, permit or cause any unauthorised disclosure of, any Confidential
Information. If requested by the Group during or after your Employment, you will execute any documents that the Group determines are necessary to protect its interests in patents, inventions and discoveries and to cooperate in good faith in any
legal proceedings to protect AstraZeneca’s intellectual property. 

  

	13.	 RESTRICTIVE COVENANTS 

 

	13.1	 You agree that you will not, without the prior written consent of the CEO: 

 

	 	13.1.1	 for the period of 12 months immediately after the Relevant Date, interfere with, solicit or endeavour to entice away
from AstraZeneca or any Affiliate any person with whom you 

  
 3 

	 	 
had personal dealings in the course of your Employment and within the Reference Period has been: 

  

	 	(a)	 a member of the Senior Executive Team (“SET”); 

 

	 	(b)	 an individual reporting directly in to you; 

 

	 	(c)	 a direct report of an individual reporting directly in to you; or 

 

	 	(d)	 an individual whom to your knowledge has been identified as high potential during a talent management discussion at SET
or by your direct reports; and 

  

	 	13.1.2	 for the period of 6 months immediately after the Relevant Date, directly or indirectly facilitate competition with any
aspect of the antibiotics, respiratory, oncology, immuno-oncology, cardiovascular or diabetes pharmaceutical business being carried on by AstraZeneca or by any Affiliate at the Relevant Date and with which you were involved in and accountable for in
the course of your Employment at any time during the Reference Period. 

  

	13.2	 None of these restrictive covenants will prohibit any activities to which the CEO has provided written consent in
advance or that are not in direct or indirect competition with any business being carried on by AstraZeneca or any Affiliate at the Relevant Date. 

  

	13.3	 You acknowledge and agree that, in the event of a breach or threatened breach of any of these restrictive covenants,
AstraZeneca will have the right to provide a copy of this Agreement to any third-party affected by the breach or threatened breach. 

  

	14.	 INFORMATION AND NOTICES 

 

	14.1	 You consent to the processing of personal data, including Sensitive Data, of which you are the subject for employment
compliance, benefits administration and other lawful purposes, details of which are specified in AstraZeneca’s data protection policy. 

  

	14.2	 Any notice or other document to be given under this Agreement shall be in writing and may be given personally to you
(including by email to your AstraZeneca email address) or to the Company Secretary of AstraZeneca or may be sent by post, in the case of AstraZeneca, to its registered office for the time being and, in your case, to your last known place of
residence. 

  

	15.	 FORMER CONTRACTS OF EMPLOYMENT 

 

	 	 This Agreement substitutes all previous contracts, agreements or arrangements between you and AstraZeneca or any
Affiliate. 

  

	16.	 CHOICE OF LAW 

 

	16.1	 This Agreement will be governed by and interpreted in accordance with English law. 

 

	16.2	 Capitalised/defined words and phrases used in this Agreement will have the meanings given to them in Schedule 1.

  

													
	 Signed on behalf of AstraZeneca
	  	 
 
	)
 )
	 
  
	  				  	 	
/s/ Leif Johansson

Chairman, AstraZeneca PLC                   
     
	 
				
	 Signed by you
	  	 
 
	)
 )
	 
  
	  				  	 	/s/ Marc Dunoyer	 

  
 4 

 SCHEDULE 1 

DEFINITIONS 
 The
following words and expressions have the meanings given to them below: 
 Affiliate means any person or entity who or which directly or
indirectly through one or more intermediaries Controls, or is Controlled by, or is under common Control with AstraZeneca PLC (registered in England and wales under number 2723534). A company “Controls” another if it holds or
controls (alone or with others) a majority of the voting rights in it, or if it is a member of the other company and has the right to appoint or remove a majority of its board of directors. 

Board means the board of directors of AstraZeneca PLC (registered in England and Wales under number 2723534) as the same may be constituted from
time to time or such other person or persons as the board of directors of AstraZeneca PLC may nominate as its representative for this purpose. 

Cause means the termination of your employment by AstraZeneca (or if you resign in anticipation of being dismissed) on account of dishonesty,
insubordination, gross mismanagement, deliberate and premeditated acts against the interests of AstraZeneca, gross or repeated violation of the Group’s policies, procedures, or recognized standards of behavior, commission of a felony, or
misconduct related to your employment or any other reason justifying your summary termination (if you would in other circumstances be entitled to notice of termination of your Employment). 

Confidential Information means information relating to the business, products, affairs and finances of AstraZeneca or of any Affiliate for the
time being confidential to it or to them and trade secrets (including, without limitation, technical data and know-how) relating to the business of AstraZeneca or of any Affiliate, details of any of its or
their suppliers, clients or customers including in particular (by way of example only and without limitation) customer requirements, prices charged to and terms of business with customers, terms of business with suppliers, marketing plans and sales
forecasts, financial information, results and other forecasts (save to the extent that these are included in published audited accounts), any of AstraZeneca’s or any Affiliate’s proposals relating to the acquisition or disposal of a
company, or a business or any part thereof or to any proposed expansion or contraction of activities, details of employees, officers, consultants and/or contractors and of the remuneration and other benefits paid to them, information relating to
research activities, clinical trial data, proposed clinical trial design, diagnostics development activities, manufacturing processes, device designs or know-how, inventions, secret processes, designs,
formulae and product lines, any information which is treated as confidential or which you are told or ought reasonably to know is confidential and any information which has been given to AstraZeneca or any Affiliate in confidence by customers,
suppliers and others. Confidential Information does not include any disclosure of information which is already in the public domain otherwise than by breach of this Agreement; or any disclosure or use authorised by the Board or required in the
proper performance by you of your duties under this Agreement or authorised or required by any applicable laws or regulations. 
 Employment
means your employment under this Agreement. 
 Group means AstraZeneca and Affiliates. 

Reference Period means the period of 12 months immediately prior to the Relevant Date. 

Relevant Date means the earlier of either the date upon which your Employment terminates or the date upon which AstraZeneca exercises the right
to place you on garden leave under clause 9.2. 
 Sensitive Data means personal data consisting of information as to racial or ethnic origin;
political opinions; religious beliefs or other beliefs of a similar nature; membership of a trade union; physical or mental health or condition; sexual life; the commission or alleged commission of any offence or any proceedings for any offence
committed or alleged to have been committed, including the disposal of such proceedings or the sentence of any court in such proceedings. 

  
 5EX-10.1

 Exhibit 10.1

 

TENDER AND SUPPORT AGREEMENT 

This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of March 6, 2017, is entered into by and among Hewlett
Packard Enterprise Company, a Delaware corporation (“Parent”), Nebraska Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and each of the persons set forth on Schedule
A hereto (each, a “Stockholder”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). 

WHEREAS, as of the date hereof, each Stockholder is the record and beneficial owner (as defined in Rule
13d-3 under the Exchange Act) of the number of (i) shares of common stock, par value $0.001 per share (the “Company Common Stock”), of Nimble Storage, Inc., a Delaware corporation (the
“Company”), (ii) options to acquire shares of Company Common Stock (the “Company Stock Options”), (iii) restricted stock units granted in respect of shares of Company Common Stock (the “Company
RSUs”) and (iv) restricted stock awards granted in respect of shares of Company Common Stock (the “Company RSAs”), in each case, set forth opposite such Stockholder’s name on Schedule A (such shares of
Company Common Stock, Company Stock Options, Company RSUs and Company RSAs set forth on Schedule A, together with any other shares of Company Common Stock or any other securities of the Company acquired by such Stockholder after the date
hereof and prior to the valid termination of this Agreement in accordance with Section 5.2 (collectively, the “After-Acquired Shares”), are referred to herein, collectively, as the “Subject
Securities” of such Stockholder); 
 WHEREAS, concurrently with the execution hereof, Parent, Merger Sub and the Company are
entering into an Agreement and Plan of Merger, dated as of the date hereof (as it may be amended from time to time, the “Merger Agreement”), which provides, among other things, for (i) Merger Sub to commence an offer to
purchase any and all of the issued and outstanding shares of Company Common Stock and (ii) the Merger of Merger Sub with and into the Company, in each case, upon the terms and subject to the conditions (including the Minimum Tender Condition)
set forth in the Merger Agreement; and 
 WHEREAS, as a condition to their willingness to enter into the Merger Agreement, and as an
inducement and in consideration for Parent and Merger Sub to enter into the Merger Agreement, each Stockholder, severally and not jointly, and on such Stockholder’s own account with respect to its Subject Securities, has agreed to enter into
this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and
agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

ARTICLE I 
 AGREEMENT TO
TENDER AND VOTE 
 1.1. Agreement to Tender. 

(a) Subject to the terms of this Agreement, during the time this Agreement is in effect, each Stockholder agrees to validly and irrevocably
tender or cause to be validly and irrevocably tendered in the Offer all of such Stockholder’s Subject Securities (other than (x) Company Stock Options that are not exercised during the term of this Agreement and (y) Company RSUs and
Company RSAs that do not vest in accordance with their terms during the term of this Agreement) pursuant to and in accordance with the terms of the Offer, free and clear of all Encumbrances (as defined below), other than Permitted Encumbrances (as
defined below). 
 (b) Without limiting the generality of the foregoing, as promptly as practicable after, but in no event later than ten
(10) Business Days after, the commencement (within the meaning of Rule 14d-2 under the Exchange Act) of the Offer, each Stockholder shall deliver pursuant to the terms of the Offer (a) a letter of
transmittal with 

 
respect to all of such Stockholder’s Subject Securities described in Section 1.1(a) above complying with the terms of the Offer (or in the case of any shares of Company Common Stock acquired
by such Stockholder subsequent to such tenth (10th) business day, or in each case if such Stockholder has not received the Offer Documents by such time, as promptly as practicable after the acquisition of such shares or receipt of the Offer
Documents, as the case may be) and (b) a certificate representing all such Subject Securities in the case of any shares that are certificated or an “agent’s message” (or such other evidence, if any, of transfer as the Paying
Agent may reasonably request) in the case of a Book-Entry Share. Each Stockholder agrees to promptly deliver any other documents or instruments that Parent or Merger Sub may reasonably require in order to effect the valid tender of such
Stockholder’s Subject Securities described in Section 1.1(a) above in accordance with the terms of the Offer. Each Stockholder agrees that, once all such Stockholder’s Subject Securities described in Section 1.1(a) above are tendered, such
Stockholder will not withdraw any of such Subject Securities from the Offer, unless and until (i) this Agreement shall have been validly terminated in accordance with Section 5.2 or (ii) the Offer shall have been
terminated, withdrawn or otherwise shall have expired. Upon the occurrence of (i) or (ii) in the preceding sentence, Parent and Merger Sub shall promptly return, and shall cause the Paying Agent to promptly return, all Subject Securities
tendered by each Stockholder. 
 1.2. Agreement to Vote. Subject to the terms of this Agreement, each Stockholder hereby
irrevocably and unconditionally agrees that, during the time this Agreement is in effect, at any annual or special meeting of the stockholders of the Company, however called, including any adjournment or postponement thereof, and in connection with
any action proposed to be taken by written consent of the stockholders of the Company, such Stockholder shall, in each case to the fullest extent that such Stockholder’s Subject Securities are entitled to vote thereon: (a) appear at each
such meeting or otherwise cause all such Subject Securities to be counted as present thereat for purposes of determining a quorum; and (b) be present (in person or by proxy) and vote (or cause to be voted), or deliver (or cause to be delivered)
a written consent with respect to, all of his or its Subject Securities (i) against any action or agreement that would reasonably be expected to (A) result in a breach of any covenant, representation or warranty or any other obligation of
the Company contained in the Merger Agreement, or of any Stockholder contained in this Agreement, or (B) result in any of the conditions set forth in Article VIII or Annex I of the Merger Agreement not being satisfied on or before the Outside
Date; (ii) against any change in the membership of the Company Board and (iii) against any Takeover Proposal and against any other action, agreement or transaction involving the Company that is intended, or would reasonably be expected, to
impede, interfere with, delay, postpone or prevent the consummation of the Offer or the Merger, including (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving the Company (other
than the Merger), (B) any sale, lease, license or transfer of a material amount of assets (including, for the avoidance of doubt, intellectual property rights, but excluding for the avoidance of doubt, any licenses of intellectual property
rights permitted by the terms of the Merger Agreement)) of the Company or any reorganization, recapitalization or liquidation of the Company, or (C) any amendment to the Company Certificate of Incorporation or Company Bylaws. Subject to the
proxy granted under Section 1.3, each Stockholder shall retain at all times the right to vote such Stockholder’s Subject Securities in such Stockholder’s sole and absolute discretion, and without any other
limitation, on any matters other than those expressly set forth in this Section 1.2 that are at any time or from time to time presented for consideration to the Company’s stockholders generally. 

1.3. Irrevocable Proxy. Solely to effect the matters described in Section 1.2, for so long as this
Agreement remains in effect, each Stockholder hereby irrevocably appoints Parent as its attorney-in-fact and proxy with full power of substitution and resubstitution, to
the full extent of such Stockholder’s voting rights with respect to all such Stockholder’s Subject Securities (which proxy is irrevocable and which appointment is coupled with an interest, including for purposes of Section 212 of the
DGCL) to vote, and to execute written consents with respect to, all such Stockholder’s Subject Securities solely on the matters described in Section 1.2, and in accordance therewith. Each Stockholder agrees to execute
any further agreement or form reasonably necessary or appropriate to confirm and effectuate the grant of the proxy contained herein. Such proxy shall automatically terminate upon the valid termination of this Agreement in accordance with
Section 5.2. Parent may terminate this proxy with respect to a Stockholder at any time in its sole and absolute discretion by written notice provided to such Stockholder. 

  
 -2- 

 ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS 

Each Stockholder represents and warrants to Parent and Merger Sub as to such Stockholder, solely on its own account and solely with respect to
its Subject Securities, on a several basis, that: 
 2.1. Authorization; Binding Agreement. 

(a) If such Stockholder is not an individual, such Stockholder is duly organized and validly existing in good standing (where such concept is
recognized under applicable Law) under the Laws of the jurisdiction in which it is incorporated or constituted and the consummation of the transactions contemplated hereby are within such Stockholder’s entity powers and have been duly
authorized by all necessary entity actions on the part of such Stockholder, and such Stockholder has all requisite power and authority to execute and deliver, and perform its obligations under, this Agreement and to consummate the transactions
contemplated hereby. If such Stockholder is an individual, such Stockholder has full legal capacity, right and authority to execute and deliver this Agreement and to perform such Stockholder’s obligations hereunder. 

(b) This Agreement has been duly and validly executed and delivered by such Stockholder and, assuming the due authorization, execution and
delivery hereof by Parent and Merger Sub, constitutes a valid and binding obligation of such Stockholder enforceable against such Stockholder in accordance with its terms, subject, as to enforceability, to bankruptcy, insolvency and other Laws of
general applicability relating to or affecting creditors’ rights and to general equity principles. 
 (c) If such Stockholder is
married, and any of the Subject Securities of such Stockholder constitute community property or otherwise need spousal or other approval for this Agreement to be legal, valid and binding, this Agreement has been duly executed and delivered by such
Stockholder’s spouse and, assuming the due authorization, execution and delivery hereof by Parent and Merger Sub, is enforceable against such Stockholder’s spouse in accordance with its terms, subject, as to enforceability, to bankruptcy,
insolvency and other Laws of general applicability relating to or affecting creditors’ rights and to general equity principles. 
 2.2.
Non-Contravention. Neither the execution and delivery of this Agreement by such Stockholder nor the consummation of the transactions contemplated hereby nor compliance by such Stockholder with
any provisions herein will (a) if such Stockholder is not an individual, violate, contravene or result in any breach of any provision of the certificate of incorporation or bylaws (or other similar governing documents) of such Stockholder,
(b) require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority on the part of such Stockholder, except for compliance with the applicable requirements of the Exchange Act and the
rules and regulations promulgated thereunder, (c) violate or result in a breach of any provisions of, or require any consent, waiver or approval or result in a default or loss of a benefit (or give rise to any right of termination,
cancellation, modification or acceleration or any event that, with the giving of notice, the passage of time or otherwise, would constitute a default or give rise to any such right) under any of the terms, conditions or provisions of any Contract or
other instrument or obligation to which such Stockholder is a party or by which such Stockholder or any of its Subject Securities is bound, (d) result (or, with the giving of notice, the passage of time or otherwise, would result) in the
creation or imposition of any Lien on such Stockholder’s Subject Securities (other than one created by Parent or Merger Sub), or (e) violate any Law or Judgment applicable to such Stockholder or by which any of its Subject Securities are
bound, other than, in the case of clauses (b) through (e), as would not reasonably be expected, either individually or in the aggregate, to materially impair, impede, delay or frustrate the ability of such Stockholder to perform such
Stockholder’s obligations hereunder. 
 2.3. Ownership of Subject Securities; Total Shares. Such Stockholder is the
record and beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of all such Stockholder’s Subject Securities and has good and marketable title to all such Subject Securities free and clear
of any Liens or any other encumbrances or restrictions whatsoever on title, transfer or exercise of any rights of a stockholder in respect of such Subject 

  
 -3- 

 
Securities (collectively, “Encumbrances”), except for any such Encumbrance that may be imposed pursuant to (a) this Agreement and (b) any applicable restrictions on
transfer under the Securities Act or any state securities law (collectively, “Permitted Encumbrances”). 
 2.4.
Voting Power. Such Stockholder has full voting power with respect to all such Stockholder’s Subject Securities (to the extent that such Subject Securities have voting rights), and full power of disposition with respect to such
Subject Securities to the extent they consist of vested shares of Company Common Stock, full power to issue instructions with respect to the matters set forth in Article I and Article IV and full power to agree to all of the matters
set forth therein, in each case with respect to all such Stockholder’s Subject Securities. 
 2.5. Reliance. Such
Stockholder understands and acknowledges that Parent and Merger Sub are entering into the Merger Agreement in reliance upon such Stockholder’s execution, delivery and performance of this Agreement. 

2.6. Absence of Litigation. With respect to such Stockholder, as of the date hereof, there is no Action pending against, or, to
the knowledge of such Stockholder, threatened in writing against such Stockholder or any of such Stockholder’s Subject Securities before or by any Governmental Authority that would reasonably be expected to prevent or materially delay or impair
the consummation by such Stockholder of the transactions contemplated by this Agreement or otherwise materially impair such Stockholder’s ability to perform its obligations hereunder. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB 

Parent and Merger Sub represent and warrant to each Stockholder that: 

3.1. Organization and Qualification. Each of Parent and Merger Sub is a duly organized and validly existing corporation in good
standing under the Laws of the jurisdiction of its organization. All of the issued and outstanding capital stock of Merger Sub is owned directly or indirectly by Parent. 

3.2. Authority for this Agreement. Each of Parent and Merger Sub has all requisite entity power and authority to execute,
deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by Parent and Merger Sub have been duly and validly authorized by all necessary entity
action on the part of each of Parent and Merger Sub, and no other entity proceedings on the part of Parent and Merger Sub are necessary to authorize this Agreement. This Agreement has been duly and validly executed and delivered by Parent and Merger
Sub and, assuming the due authorization, execution and delivery by the Stockholder, constitutes legal, valid and binding obligation of each of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms,
subject, as to enforceability, to bankruptcy, insolvency and other Laws of general applicability relating to or affecting creditors’ rights and to general equity principles. 

ARTICLE IV 
 ADDITIONAL
COVENANTS OF THE STOCKHOLDERS 
 Each Stockholder hereby covenants and agrees that until the termination of this Agreement: 

4.1. No Transfer; No Inconsistent Arrangements. 

(a) Each Stockholder agrees that such Stockholder shall not take any action that would result in a breach of any representation or warranty of
such Stockholder contained herein or have the effect of preventing or disabling 

  
 -4- 

 
such Stockholder from performing any of its obligations under this Agreement or would reasonably be expected to materially impede or materially delay the performance by any Stockholder of its
obligations under this Agreement. 
 (b) Except as provided hereunder or under the Merger Agreement, from and after the date hereof and
until this Agreement is terminated, such Stockholder shall not, directly or indirectly, (i) create or permit to exist any Encumbrance, other than Permitted Encumbrances, on any of such Stockholder’s Subject Securities, (ii) transfer,
sell, assign, gift, hedge, pledge or otherwise dispose of, or enter into any derivative arrangement with respect to (collectively, “Transfer”), any of such Stockholder’s Subject Securities, or any right or interest therein (or
consent to any of the foregoing), (iii) enter into any Contract with respect to any Transfer of such Stockholder’s Subject Securities or any interest therein, (iv) grant or permit the grant of any proxy, power-of-attorney or other authorization or consent in or with respect to any such Stockholder’s Subject Securities or (v) deposit or permit the deposit of any of such Stockholder’s Subject
Securities into a voting trust or enter into a voting agreement or arrangement with respect to any of such Stockholder’s Subject Securities; provided that such Stockholder may (A) if such Stockholder is a partnership, limited
liability company or corporation, distribute Subject Securities to its partners, members, shareholders, equity holders or affiliated entities (as applicable), but only if and to the extent the recipients thereof agree to be bound by the obligations
set forth herein with respect to such Subject Securities as if they were Stockholders hereunder, with Parent and Merger Sub named as express third-party beneficiaries of such agreements, (B) if such Stockholder is an individual, Transfer any
Subject Securities to any member of such Stockholder’s immediate family, or to a trust for the benefit of such Stockholder or any member of such Stockholder’s immediate family, (C) Transfer any Subject Securities for charitable
purposes as charitable gifts or donations, and (D) Transfer any Subject Securities upon the death of such Stockholder (each, a “Permitted Transfer”). Any action taken in violation of the immediately preceding sentence shall be
null and void ab initio. If any involuntary Transfer of any of such Stockholder’s Subject Securities shall occur (including a sale by such Stockholder’s trustee in any bankruptcy, or a sale to a purchaser at any creditor’s or
court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Subject Securities subject to all of the restrictions, liabilities and
rights under this Agreement, which shall continue in full force and effect until valid termination of this Agreement. 
 (c) Such
Stockholder agrees that it shall not, and shall cause each of its affiliates not to, become a member of a “group” (as defined under Section 13(d) of the Exchange Act) for the purpose taking any actions inconsistent with the transactions
contemplated by this Agreement or the Merger Agreement. Notwithstanding Section 4.1(b), such Stockholder may make Transfers of its Subject Securities as Parent may agree in writing in its sole discretion. 

4.2. No Exercise of Appraisal Rights. Such Stockholder forever waives and agrees, as to himself or itself, not to exercise any
appraisal rights or dissenters’ rights in respect of such Stockholder’s Subject Securities that may arise in connection with the Merger. 

4.3. Documentation and Information. Such Stockholder shall not make any public announcement regarding this Agreement and the
transactions contemplated hereby without the prior written consent of Parent (such consent not to be unreasonably withheld, conditioned or delayed), except as may be required by applicable Law (provided that reasonable notice of any such
disclosure will be provided to Parent to the extent reasonably practicable). Such Stockholder consents to and hereby authorizes Parent and Merger Sub to publish and disclose in all documents and schedules filed with the SEC, and any press release or
other disclosure document that is required in connection with the Offer, the Merger and any transactions contemplated by the Merger Agreement, such Stockholder’s identity and ownership of the Subject Securities, the existence of this Agreement
and the nature of such Stockholder’s commitments and obligations under this Agreement, and such Stockholder acknowledges that Parent and Merger Sub may, in Parent’s sole discretion, file this Agreement or a form hereof with the SEC. Such
Stockholder agrees, as to himself or itself, to promptly give Parent any information it may reasonably request for the preparation of any such disclosure documents, and such Stockholder agrees to promptly notify Parent of any required corrections
with respect to any written information supplied by such 

  
 -5- 

 
Stockholder specifically for use in any such disclosure document, if and to the extent that any such information shall have become false or misleading in any material respect. 

4.4. Adjustments. In the event of any stock split, stock dividend, merger, reorganization, recapitalization, reclassification,
combination, exchange of shares or the like of the capital stock of the Company affecting the Subject Securities, the terms of this Agreement shall apply to the resulting securities. 

4.5. Waiver of Certain Actions. Each Stockholder hereby agrees, as to himself or itself, not to commence or participate in, and
to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against the Company, Parent, Merger Sub or any of their respective successors (a) challenging the validity of, or
seeking to enjoin or delay the operation of, any provision of this Agreement or the Merger Agreement (including any claim seeking to enjoin or delay the Offer Closing or the Merger Closing) or (b) alleging a breach of any duty of the Company
Board in connection with the Merger Agreement, this Agreement or the transactions contemplated thereby or hereby. 
 4.6. No
Solicitation. Each Stockholder shall not, and shall cause its controlled Affiliates not to, and shall use reasonable best efforts to cause its and their respective Representatives not to, directly or indirectly, (i) solicit, initiate,
knowingly facilitate or knowingly encourage the submission or announcement of any inquiries, proposals or offers that constitute or would reasonably be expected to lead to any Takeover Proposal, (ii) provide any
non-public information concerning the Company to any person or group in connection with any Takeover Proposal, or engage in any discussions or negotiations with respect to any Takeover Proposal (other than to
inform any relevant third party of the restrictions hereunder and under the Merger Agreement), (iii) otherwise cooperate with or knowingly assist or participate in, or knowingly facilitate, any such inquiries, proposals, offers, discussions or
negotiations or (iv) resolve or agree to do any of the foregoing. Each Stockholder shall, and shall cause its controlled Affiliates to, and shall use reasonable best efforts to cause its and their respective Representatives to, immediately
cease and cause to be terminated any solicitation, encouragement, discussion or negotiation with any person or groups that may be ongoing with respect to any Takeover Proposal or potential Takeover Proposal. 

ARTICLE V 
 MISCELLANEOUS

 5.1. Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given and received (a) upon receipt, if delivered personally, (b) two (2) Business Days after deposit in the mail, if sent by registered or certified mail, (c) on the next Business Day after deposit with an overnight courier, if
sent by overnight courier (with proof of delivery), (d) upon transmission and confirmation of receipt, if sent by email transmission prior to 6:00 p.m., local time, in the place of receipt, or (e) on the next Business Day following
transmission and confirmation of receipt, if sent by email transmission after 6:00 p.m., local time, in the place of receipt; provided that the notice or other communication is sent to the address or email address set forth (i) in the
case to Parent or Merger Sub, to the address or email address set forth in Section 11.03 of the Merger Agreement and (ii) if to a Stockholder, to such Stockholder’s address or email address set forth on a signature page hereto, or to
such other address or email address as such party may hereafter specify for the purpose by notice to each other party hereto. 
 5.2.
Termination. With respect to each Stockholder, this Agreement shall terminate automatically, without any notice or other action by any person, upon the first to occur of (a) the valid termination of the Merger Agreement in
accordance with its terms, (b) the Acceptance Time, (c) the mutual written consent of Parent and such Stockholder and (d) any amendment to the Offer or the Merger Agreement, or waiver of the Company’s rights under the Merger
Agreement, that, in each case, results in a decrease of the Offer Price or the Merger Consideration, a change in the form of consideration payable in connection with the Offer or the Merger or a change in the treatment of such Stockholder’s
Company Stock Options, Company RSUs or Company RSAs 

  
 -6- 

 
pursuant to the Merger Agreement ( unless such Stockholder consents in writing in advance to such amendment or waiver). Upon termination of this Agreement, no party shall have any further
obligations or liabilities under this Agreement; provided that (i) nothing set forth in this Section 5.2 shall relieve any party from liability for any willful breach of this Agreement prior to termination
hereof and (ii) the provisions of this Article V (other than Section 5.14) shall survive any termination of this Agreement. 

5.3. Amendments and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing
and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

5.4. Expenses. All fees and expenses incurred in connection herewith and the transactions contemplated hereby shall be paid by
the party incurring such fees and expenses, whether or not the Offer or the Merger is consummated. 
 5.5. Entire Agreement;
Assignment. This Agreement, together with Schedule A, and the other documents and certificates delivered pursuant hereto, constitute the entire agreement, and supersede all prior agreements and understandings, both written and oral,
among the parties with respect to the subject matter of this Agreement. Neither this Agreement nor any of the rights, interest or obligations hereunder shall be assigned, in whole or in part, by operation of law or otherwise by any of the parties
without the prior written consent of the other parties, and any such assignment without consent shall be null and void; provided that Parent or Merger Sub may transfer or assign all or any part of their respective rights and obligations to
any direct or indirect wholly owned Subsidiary of Parent (it being understood that such transfer or assignment shall not relieve Parent of its obligations hereunder). 

5.6. Enforcement of the Agreement. The parties agree that irreparable damage would occur in the event that any Stockholder did
not perform any of the provisions of this Agreement in accordance with their specific terms or otherwise breached any such provisions. It is accordingly agreed that Parent and Merger Sub shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in addition to any other remedy to which they are entitled at law or in equity. Any and all remedies herein expressly conferred upon Parent and Merger
Sub will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by Parent or Merger Sub of any one remedy will not preclude the exercise of any other remedy. 

5.7. Jurisdiction; Service of Process; Waiver of Jury Trial. 

(a) Each of the parties hereto irrevocably (i) submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware
or, if such court lacks subject matter jurisdiction, the United States District Court sitting in New Castle County in the State of Delaware, for the purpose of any Action directly or indirectly based upon, relating to or arising out of this
Agreement or any transaction contemplated hereby, or the negotiation, execution or performance hereof and (ii) agrees that all claims in respect to such Action shall be brought in, and may be heard and determined, exclusively in such state or
federal courts. Each of the parties hereto irrevocably and unconditionally waives any objection to the laying of venue and any defense of inconvenient forum to the maintenance of, any Action so brought. Each of the parties hereto agrees that a final
judgment in any Action may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each of the parties hereto irrevocably consents to the service of the summons and complaint and any other process in any
other Action relating to the transactions contemplated by this Agreement, on behalf of itself or its property, by U.S. registered mail in accordance with Section 5.1. Nothing in this Section 5.7
shall affect the right of any party hereto to serve legal process in any other manner permitted by Law. 

  
 -7- 

 (b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT
IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN ANY ACTION DIRECTLY OR INDIRECTLY BASED UPON, RELATING TO OR
ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE HEREOF OR THEREOF. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (III) EACH PARTY MAKES
THIS WAIVER VOLUNTARILY AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

5.8. Governing Law. This Agreement and any Action (whether at Law, in contract or in tort) that may directly or indirectly be
based upon, relate to or arise out of this Agreement or any transaction contemplated hereby, or the negotiation, execution or performance hereof, shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without
giving effect to any Laws that might result in the application of the Law of another jurisdiction. 
 5.9. Descriptive
Headings. The descriptive headings herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement. 

5.10. Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto, and
nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this Agreement. 

5.11. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any
rule of Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the
parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner. 

5.12. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of
which, taken together, shall constitute one and the same agreement. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall
be deemed an original. 
 5.13. Interpretation. The words “hereof,” “herein,” “hereby,”
“herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement, and article, section, paragraph and schedule references are to
the articles, sections, paragraphs and schedules of this Agreement unless otherwise specified. Whenever the words “include,” “includes” or “including” are used in this Agreement they shall be deemed to be followed by
the words “without limitation.” The words describing the singular number shall include the plural and vice versa, words denoting either gender shall include both genders and words denoting natural persons shall include all Persons and vice
versa. The phrases “the date of this Agreement,” “the date hereof,” “of even date herewith” and terms of similar import, shall be deemed to refer to the date set forth in the preamble to this Agreement. Any reference in
this Agreement to a date or time shall be deemed to be such date or time in New York City, unless otherwise specified. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this
Agreement. 

  
 -8- 

 5.14. Further Assurances. Each Stockholder will execute and deliver, or cause to be
executed and delivered, all further documents and instruments and use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Laws and regulations, to perform its
obligations under this Agreement. 
 5.15. Capacity as Stockholder. Each Stockholder signs this Agreement solely in such
Stockholder’s capacity as a record and beneficial owner of Subject Securities, and not, if applicable, in such Stockholder’s capacity as a director, officer or employee of the Company or any of its Subsidiaries. Notwithstanding anything
herein to the contrary, nothing herein shall in any way restrict or limit a director or officer of the Company in the taking of any actions (or failure to act) in his or her capacity as a director, officer or employee of the Company, or in the
exercise of his or her fiduciary duties as a director, officer or employee of the Company, or prevent or be construed to create any obligation on the part of any director, officer or employee of the Company from taking any action in his or her
capacity as such director, officer or employee. 
 5.16. No Agreement Until Executed. This Agreement shall not be effective
unless and until (i) the Merger Agreement is executed and delivered by all parties thereto and (ii) this Agreement is executed by all parties hereto. 

5.17. Stockholder Obligation Several and Not Joint. The obligations of each Stockholder hereunder shall be several and not
joint, and no Stockholder shall be liable for any breach of the terms of this Agreement by any other Stockholder. 
 [Signature pages
follow.] 

  
 -9- 

 IN WITNESS WHEREOF, each of the parties has executed or caused this Agreement to be executed on
its behalf by its officer thereunto duly authorized, all as of the date first above written. 
  

			
	HEWLETT PACKARD ENTERPRISE COMPANY
		
	By:	 	 /s/ Rishi Varma

	Name:	 	Rishi Varma
	Title:   Senior Vice President, Deputy General Counsel & Assistant Secretary
	
	NEBRASKA MERGER SUB, INC.
		
	By:	 	 /s/ Rishi Varma

	Name:	 	Rishi Varma
	Title:	 	President & Secretary

  
 [Signature Page to Tender and
Support Agreement] 

 
			
	STOCKHOLDERS:
	
	SURESH VASUDEVAN
	
	 /s/ Suresh Vasudevan

	Email: suresh@nimblestorage.com
	Address:	 	 c/o Nimble Storage, Inc.
 211 River Oaks
Parkway
 San Jose, CA 95134

  
 [Signature Page to Tender and
Support Agreement] 

									
		 		 		 	STOCKHOLDERS:
			
	UMESH MAHESHWARI	 		 	 THE UMESH MAHESHWARI 2015

REVOCABLE TRUST

				
		 		 		 	
	 /s/ Umesh Maheshwari

Email: umesh@nimblestorage.com
	 		 	 /s/ Umesh Maheshwari

	Address: 	 	c/o Nimble Storage, Inc.	 		 	Name:	 	Umesh Maheshwari
		 	211 River Oaks Parkway	 		 	Title:	 	Trustee
		 	San Jose, CA 95134	 		 		 	
				
		 		 		 	THE UMESH MAHESHWARI 2015 GRANTOR RETAINED ANNUITY TRUST
				
		 		 		 	 /s/ Umesh Maheshwari

		 		 		 	Name:	 	Umesh Maheshwari
		 		 		 	Title:	 	Trustee
				
		 		 		 	THE MAHESHWARI CHILDREN’S TRUST
				
		 		 		 	 /s/ Umesh Maheshwari

		 		 		 	Name:	 	Umesh Maheshwari
		 		 		 	Title:	 	Trustee

 [Signature Page to Tender and Support
Agreement] 

							
		 		 	STOCKHOLDERS:
			
	VARUN MEHTA	 		 	 THE MEHTA FAMILY TRUST U/A
 DATED
11/06/2006 VARUN MEHTA &
 MALA MEHTA TRUSTEES

	 /s/ Varun Mehta
	 		 		 	
	Email: varun@nimblestorage.com	 		 		 	
	Address: c/o Nimble Storage, Inc.	 		 	 /s/ Varun Mehta

	               211 River Oaks Parkway	 		 	Name:	 	Varun Mehta
	               San Jose, CA 95134	 		 	Title:	 	Trustee
			
		 		 	THE JAI VIR MEHTA 2012 GST TRUST
			
		 		 	 /s/ Varun Mehta

		 		 	Name:	 	Varun Mehta
		 		 	Title:	 	Trustee
			
		 		 	THE JAI VIR MEHTA TRUST
			
		 		 	 /s/ Varun Mehta

		 		 	Name: 	 	Varun Mehta
		 		 	Title:	 	Trustee
			
		 		 	THE KIMAYA JIA MEHTA 2012 GST TRUST
			
		 		 	 /s/ Varun Mehta

		 		 	Name:	 	Varun Mehta
		 		 	Title:	 	Trustee
			
		 		 	THE KIMAYA JIA MEHTA TRUST
			
		 		 	 /s/ Varun Mehta

		 		 	Name:	 	Varun Mehta
		 		 	Title:	 	Trustee
		 		 		 	
		 		 		 	

  
  

[Signature Page to Tender and Support Agreement] 

			
	  
 STOCKHOLDERS:
	  	
		
	Sequoia Capital XII	  	
	Sequoia Technology Partners XII	  	
	Sequoia Capital XII Principals Fund	  	

  

			
	By:	 	SC XII Management, LLC
		 	A Delaware Limited Liability Company
		 	General Partner of Each

  

			
	 By:
	 	 /s/ Jim Goetz

		 	Managing Member

  

			
	 SC US GF V HOLDINGS, LTD.
 a
Cayman Islands exempted company

			
		
	By:	 	SEQUOIA CAPITAL U.S. GROWTH FUND V, L.P.
		 	SEQUOIA CAPITAL USGF PRINCIPALS FUND V, L.P.
		 	both Cayman Islands exempted limited partnerships, its Members
		
	By:	 	SCGF V MANAGEMENT, L.P.,
		 	a Cayman Islands exempted limited partnership, its General Partner
		
	By:	 	SC US (TTGP), LTD.,
		 	a Cayman Islands exempted company, its General Partner

  

			
	 By:
	  	 /s/ Jim Goetz

			
	 Name:
	  	James J. Goetz
	 Title:
	  	Director
		
		  	 2800 Sand Hill Road Suite 101
 Menlo Park, CA
94025
 Compliance@sequoiacap.com

 Schedule A 

 

									
	 Name of Stockholder
	  	Shares of
Company
Common
Stock	  	Company
Stock
Options	  	Company
RSUs	  	Company
RSAs
	 Suresh Vasudevan
	  	767,873	  	2,594,935	  	457,773	  	0
					
	 Umesh Maheshwari
	  	75,858	  	375,092	  	341,950	  	0
					
	 The Umesh Maheshwari 2015 Revocable Trust
	  	2,163,258	  	0	  	0	  	0
					
	 The Umesh Maheshwari 2015 Grantor Retained Annuity Trust
	  	1,500,000	  	0	  	0	  	0
					
	 The Maheshwari Children’s Trust
	  	1,108,900	  	0	  	0	  	0
					
	 Umesh Maheshwari (Total)
	  	4,848,016	  	375,092	  	341,950	  	0
					
	 Varun Mehta
	  	104	  	200,000	  	341,950	  	0
					
	 The Mehta Family Trust U/A Dated 11/06/2006 Varun Mehta & Mala Mehta Trustees
	  	4,133,340	  	0	  	0	  	0
					
	 The Jai Vir Mehta 2012 GST Trust
	  	600,000	  	0	  	0	  	0
					
	 The Jai Vir Mehta Trust
	  	650,000	  	0	  	0	  	0
					
	 The Kimaya Jia Mehta 2012 GST Trust
	  	600,000	  	0	  	0	  	0
					
	 The Kimaya Jia Mehta Trust
	  	650,000	  	0	  	0	  	0
					
	 Varun Mehta (Total)
	  	6,633,444	  	200,000	  	341,950	  	0
					
	 Sequoia Capital XII, L.P.
	  	5,075,096	  	0	  	0	  	0
					
	 Sequoia Technology Partners XII, L.P.
	  	189,900	  	0	  	0	  	0
					
	 Sequoia Capital XII Principals Fund, LLC
	  	542,412	  	0	  	0	  	0
					
	 SC US GF V Holdings, Ltd.
	  	662,700	  	0	  	0	  	0
					
	 Sequoia Capital (Total)
	  	6,470,108	  	0	  	0	  	0

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]